LitCovid-sample-sentences  

PMC:7205724 / 21808-23259 JSONTXT 25 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T176 0-41 Sentence denotes 6.2 Targeting pro-inflammatory cytokines
T177 43-61 Sentence denotes 6.2.1 Hypothesis:
T178 62-112 Sentence denotes A mAb against IL6 can attenuate hyper inflammation
T179 113-441 Sentence denotes Tocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis.
T180 442-523 Sentence denotes It is safe and effective for both adults and children two years of age and older.
T181 525-542 Sentence denotes 6.2.2 Rationale:
T182 543-622 Sentence denotes Tocilizumab can treat lung injury in patients with critical and severe COVID-19
T183 623-770 Sentence denotes In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy.
T184 771-989 Sentence denotes Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels.
T185 990-1048 Sentence denotes Also, lung lesion opacity was absorbed in 90% of patients.
T186 1049-1128 Sentence denotes Neither serious adverse effects nor deaths occurred with tocilizumab treatment.
T187 1129-1235 Sentence denotes There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19.
T188 1236-1451 Sentence denotes Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28].